The ARCADIA trial compared apixaban to aspirin in ESUS patients with atrial cardiopathy, finding no improvement in recurrent stroke rates or safety outcomes. The study presenter highlighted the lack of benefit of apixaban over aspirin in this patient population. Secondary analyses will be conducted to explore potential explanations. Similar results were seen in previous ESUS trials. The definition of atrial cardiopathy and the heterogeneity of patients were discussed. The failure of anticoagulation in previous trials led to the hypothesis of different underlying etiologies requiring varied antithrombotic therapy. The trial methodology, patient characteristics, outcomes, and safety results were detailed. Twitter reactions from experts were also included.
לשפה אחרת
מתוכן המקור
www.medscape.com
תובנות מפתח מזוקקות מ:
by Liam Davenpo... ב- www.medscape.com 05-29-2023
https://www.medscape.com/viewarticle/992525שאלות מעמיקות